In accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ('LODR Regulations') we hereby submit the outcome of the Board Meeting ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board approved unaudited results for Q3 and nine months ended December 31, 2025. Total revenue from operations jumped sharply to Rs. 484.61 lakh in Q3FY26 from Rs. 77.34 lakh in Q3FY25, and to Rs. 1,073.23 lakh for 9MFY26 from Rs. 167.95 lakh a year earlier. However, the net loss widened to Rs. 295.14 lakh in Q3 (vs Rs. 192.20 lakh) and Rs. 874.56 lakh for 9MFY26 (vs Rs. 478.13 lakh). The board also approved increasing authorised capital from Rs. 38 crore to Rs. 50 crore and issued 48.25 lakh equity shares at Rs. 20 each (Rs. 9.65 crore) on a preferential basis to 7 investors, plus 45 lakh warrants at Rs. 20 each (Rs. 9 crore) to MD and Promoter Deepa Tracy. Additionally, 45,442 partly paid-up shares from a rights issue were forfeited for non-payment of call money.
Existing shareholders will face significant equity dilution from the combined preferential allotments and warrant conversions, though promoter participation through warrants signals some confidence. Despite the sharp revenue growth, the company continues to post widening losses, suggesting the capital raise is aimed at funding operations rather than rewarding shareholders.